H&T Presspart Manufacturing

What H&T Presspart Manufacturing does

H&T Presspart Manufacturing is a specialist contract manufacturer of drug delivery devices and pharmaceutical components, headquartered in Marsberg, Germany as a division of the family-owned Heitkamp & Thumann Group. Founded in 1970 and acquired by the Group in 2002, the company operates four European manufacturing sites in Germany (Marsberg), Spain (Tarragona, producing over 1 billion devices and components annually), Switzerland (Nidau) and the United Kingdom (Blackburn), plus a recently acquired US facility in Lake Geneva, Wisconsin. Its components feature in over 85% of the world's metered-dose inhalers, and the company maintains sales representation in India, China and Latin America.

The product portfolio spans metered-dose inhaler canisters, actuators and dose counters, capsule-based dry powder inhalers (PowdAir Plus licensed from Hovione, and the Sunriser DPI platform), multi-component drug delivery devices, the Vytal ready-to-use snap-fit closure for parenteral biologics, and pre-fillable syringe systems (via Plas-Tech Engineering). Core manufacturing capabilities include high-volume precision deep-drawn metal forming, injection moulding, high-speed automated assembly in ISO 7 and ISO 8 cleanrooms, GMP-compliant filling for low global-warming-potential propellants (HFA-152a and HFO-1234ze), and proprietary plasma surface treatment for MDI canisters. The company also offers device development, scale-up, industrialization, regulatory and analytical services.

The business model is B2B enterprise contract manufacturing on quote-based pricing, combining recurring component sales (hardware) with project-based development and analytical services. Customers are leading global pharmaceutical companies requiring qualified, single-source supply for inhalation and parenteral products; long-tenure relationships are anchored by multi-year qualification cycles, regulatory certification (ISO 13485, ISO 15378, cGMP), and dedicated customer production facilities.

Name

H&T Presspart Manufacturing

Legal name

H&T Presspart Holding GmbH

Website

https://presspart.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

101–250 employees

Short description

H&T Presspart Manufacturing is a specialist B2B contract manufacturer of metered-dose inhaler components, dry powder inhalers, and parenteral drug delivery devices for global pharmaceutical companies, producing over one billion devices annually across European and US sites.

Ownership category

akta.pro rank

Product category

Pharmaceutical Component and Drug Delivery Device Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG), Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical component manufacturing
• Drug delivery devices
• Metered-dose inhalers
• Dry powder inhalers
• Parenteral drug delivery

Headquarters

HQ city

Lancaster

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Component Manufacturing: H&T Presspart generates revenue through manufacturing and supplying precision pharmaceutical components including MDI canisters, actuators, dose counters, and deep-drawn metal components. The company produces over 1 billion devices and components annually across its manufacturing sites.
2. Drug Delivery Device Manufacturing: Manufacturing and supply of multi-component drug delivery devices including dry powder inhalers, soft mist inhalers, and parenteral devices. Products are manufactured in ISO 7 and ISO 8 cleanrooms with high-speed automated assembly.
3. Contract Development and Manufacturing Services: Comprehensive services including device development, small series and pilot phase support, scale-up and industrialization, program management, regulatory support, and analytical services.
4. GMP Filling Services: GMP-compliant filling of MDI batches for clinical trials and development programs using low GWP propellants (HFA-152a and HFO-1234ze).

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

H&T Presspart manufactures precision pharmaceutical components and drug delivery devices — including MDI canisters, actuators and dose counters (present in over 85% of the world's MDIs), capsule-based dry powder inhalers (PowdAir Plus, Sunriser DPI), the Vytal RTU snap-fit closure for advanced parenteral therapeutics, pre-fillable syringe systems, and multi-component devices — for global pharmaceutical customers. Manufacturing is performed in ISO 7 and ISO 8 cleanrooms across four European plants and, since November 2025, a Wisconsin facility, with production exceeding 1 billion devices and components annually and supported by integrated device development, industrialization, regulatory, and analytical services.

Product overview

H&T Presspart is a world leader in manufacturing drug delivery devices and pharmaceutical components with over 50 years of experience. The product portfolio centers on inhalation drug delivery (MDI components, Dry Powder Inhalers including PowdAir Plus and Sunriser platform), parenteral solutions (Vytal RTU snap-fit closures, pre-fillable syringes via Equinox), multi-component drug delivery devices, diagnostics, and low-carbon MDIs with low GWP propellants. Core manufacturing capabilities include deep-drawn metal components, precision injection moulding, automated assembly in ISO 7/8 cleanrooms, and plasma surface treatment technology. The company offers comprehensive development services from concept through industrialization and commercial supply, supported by analytical testing and regulatory expertise. Manufacturing operations span Blackburn (UK), Marsberg (Germany), Tarragona (Spain), Nidau (Switzerland), with sales representation in India, China, USA, and Uruguay. Recent expansion includes Plas-Tech Engineering acquisition for pre-fillable syringe capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Vytal: Ready-to-use (RTU) snap-fit closure system for advanced therapeutics including biologics, viral vectors, mRNA, and cell therapies.
• Vytal RTU
• PowdAir Plus
• Sunriser
• Plasma MDI Cans

Products and services

• Vytal® RTU Snap-fit Closure Ready-to-use snap-fit closure system for parenteral applications including biologics, viral vectors, mRNA, ADCs, cell and gene therapies, with container closure integrity (CCI) even at -80°C, reduced particle formation, and tamper evidence. Targeted at pharmaceutical manufacturers developing advanced parenteral therapeutics.
• Pre-fillable Syringes (Equinox / Plas-Tech Engineering) Pre-fillable syringe systems manufactured through the Plas-Tech Engineering acquisition, designed for safe and efficient drug delivery in parenteral applications and targeted at North American pharmaceutical customers requiring high-quality ready-to-fill syringe sub-assemblies.
• MDI Components (Canisters, Actuators, Dose Counters) Full range of metered-dose inhaler components including deep-drawn aluminium canisters, injection-moulded actuators, and 3M-licensed dose counters. Over 85% of the world's MDIs feature H&T Presspart components, supplied to global pharmaceutical companies commercializing respiratory drug products.
• PowdAir Plus Dry Powder Inhaler Compact capsule-based DPI with only four components and no metal parts, designed for affordability and ease of use in emerging markets and supplied to generic and branded respiratory pharma manufacturers under Hovione Technology patent license.
• Sunriser DPI Platform High-performance capsule-based DPI platform co-developed with Hovione Technology, providing efficient delivery of diverse formulations including carrier-based, spray-dried, and spray-dried/carrier-free particles, with a modular approach for optimized capsule movement and finer particle fractions than currently available market devices.
• Low Carbon MDIs (Low-GWP Propellant Solutions) MDIs and supporting components utilizing low global warming potential propellants (HFA-152a and HFO-1234ze), supplied to pharmaceutical customers seeking to transition away from high-GWP propellants ahead of regulatory phase-outs, with GMP filling and analytical services included.
• Multi-Component Drug Delivery Devices Complex drug delivery devices combining multiple components for injection, inhalation, and diagnostic applications, manufactured via precision injection moulding and high-speed automated assembly in ISO 7 and ISO 8 cleanrooms and supplied to pharmaceutical and diagnostic OEMs.
• Diagnostic Products Diagnostic devices and components including gel cards for blood typing and antibody screening plus custom in-vitro diagnostic consumables, manufactured to high dimensional stability and cosmetic standards for diagnostic OEMs and healthcare companies.
• Drug Delivery Device Development Services Comprehensive services spanning device development, small-series and pilot-phase support, scale-up and industrialization, program management, regulatory support, analytical services, and smart-solution development, provided to pharmaceutical customers to support each program from concept through market launch.
• Analytical Services Full spectrum of analytical testing for MDI and DPI products including Delivered Dose Uniformity (DDU), aerodynamic Particle Size Distribution (APSD), and Spray Pattern and Plume Geometry (SPPG), offered to pharmaceutical customers for product development, release, and regulatory support.
• GMP Manufacturing & Assembly Services High-precision contract manufacturing and assembly services delivered in ISO 7 and ISO 8 cleanrooms, including deep-drawn metal component manufacturing, precision injection moulding, and high-speed automated assembly under EU/FDA cGMP.

Quantifiable outcome

• Plasma MDI cans reduce carbon footprint by 10x compared to anodized cans
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Plas-Tech EngineeringcoreStrategic or Co-development Partner · 4 November 2025H&T Presspart acquired majority stake in Plas-Tech Engineering on November 4, 2025. Wisconsin-based company specializing in pre-fillable syringe systems, expanding H&T Presspart's parenteral capabilities.
• invoX PharmacoreStrategic or Co-development Partner · 1 October 2024Strategic partnership to manufacture the device sub assembly for commercialization of the Softhaler. H&T Presspart provides manufacturing expertise for the device sub assembly.
• Tarragona Chamber of CommerceminorGTM or Marketing Partner · 1 October 2024Strategic partnership renewal for mutual support and business development in the Tarragona region.
• BespakcoreStrategic or Co-development Partner · 29 April 2024Collaboration to accelerate industry's transition from existing pMDI formulations to low GWP propellants. Partnership provides GMP filling capabilities and development support for clinical trials with HFA-152a and HFO-1234ze propellants. Combines H&T Presspart's component expertise with Bespak's valve expertise and formulation capabilities.
• Hovione TechnologycoreStrategic or Co-development Partner · 1 May 2023Extended collaboration to develop new high-performance dry powder inhaler technology platform including the Sunriser DPI platform. Hovione provides patented inhaler technology while H&T Presspart handles large-scale industrialization and distribution. Millions of patients treated annually with Hovione Technology's innovative inhaler technology.
• OzUKminorStrategic or Co-development Partner · 1 September 2022Partnership to offer full service in Metered-Dose Inhaler (MDI) development, combining OzUK's expertise with H&T Presspart's manufacturing capabilities.
• Bilim PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 September 2020Turkish pharmaceutical company launched Ventofor Combi Fix delivered by PowdAir Plus DPI. Collaboration with Hovione Technology and H&T Presspart for Turkish market launch of budesonide formoterol for asthma and COPD.
• 3M Drug Delivery SystemscoreTechnology or Integration · 14 August 2014Licensed to sell 3M Dose by Dose Counter and Dose Indicator technology, adding to expanding portfolio of MDI actuator capabilities. The technology was first integrated dose counter approved by FDA for third-party MDI developments.
• Heitkamp & Thumann GroupcoreOthersH&T Presspart is a division of the Heitkamp & Thumann Group, a leading global partner for precision-formed components. The family-owned group comprises 15 companies in 9 countries with 1,800 employees.

Scale indicators6 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• Gerresheimer: Pharmaceutical and medical packaging manufacturer producing glass and plastic primary packaging, pre-fillable syringes and drug delivery devices — directly comparable to H&T Presspart's pre-fillable syringe expansion and primary packaging components for injectables.
• Bespak (now part of Recipharm/Euroapi ecosystems; independently the former Consort Medical): Drug delivery device and valve manufacturer with deep pMDI valve expertise and a strategic HFA-152a/HFO-1234ze transition partnership with H&T Presspart (April 2024); directly comparable in MDI valve/component manufacturing and low-GWP propellant readiness.
• Stevanato Group: Manufacturer of glass primary packaging, pre-fillable syringes and drug delivery devices for the pharmaceutical industry, including integrated solutions for biologics — directly comparable to H&T Presspart's Vytal closure, pre-fillable syringes and high-precision device manufacturing.
• Schott Pharma: Specialist in pharmaceutical glass and polymer primary packaging including vials, syringes, cartridges and ampoules for injectables — comparable to H&T Presspart's primary packaging components and parenteral device expansion targeting biologics.
• Aptar Pharma: Major drug delivery device manufacturer with leading positions in metered-dose inhaler valves and actuators, dry powder and nasal inhalers, and injectable platforms — directly comparable to H&T Presspart's MDI, DPI and parenteral device businesses serving the same pharma customers.
• West Pharmaceutical Services: Global leader in primary packaging components and drug delivery systems for injectable and inhalation pharmaceuticals, including elastomeric closures and pre-fillable syringe components — directly comparable to H&T Presspart's Vytal closure, pre-fillable syringe business and respiratory component portfolio.

Broad incumbents

• Catalent (Novo Holdings): Large CDMO with inhalation and biologics fill-finish capabilities serving the same pharma customers as H&T Presspart; comparable overlap in pMDI development, GMP filling and parenteral drug product services.
• Becton Dickinson (BD): Large medical device and pharmaceutical systems company with a major pre-fillable syringe, injection device and drug delivery franchise — overlapping with H&T Presspart's parenteral and device expansion while operating across a much broader healthcare portfolio.

Emerging players

• Nemera: Drug delivery device developer and manufacturer focused on inhalation (pMDIs, DPIs, nasal), injectable and ophthalmic devices — directly comparable in inhalation and parenteral device categories, though smaller and more specialized than H&T Presspart.

Regional players

• Bormioli Pharma: European-based manufacturer of pharmaceutical primary packaging (vials, bottles, syringes) and drug delivery devices — comparable in primary packaging and parenteral components, primarily serving European customers like H&T Presspart's legacy markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCQ2M9rXBiDuhPsLC6QsT_Gg/videos
• Facebookfacebook.com/Presspart
• LinkedInlinkedin.com/company/presspart
• Xx.com/Presspart

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H&T Presspart Manufacturing